Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BCC Research | PRODUCT CODE: 2059971

Cover Image

PUBLISHER: BCC Research | PRODUCT CODE: 2059971

Chronic Kidney Disease: Global Markets and Technologies

PUBLISHED:
PAGES: 152 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4650
PDF & Excel (2-5 Users)
USD 5580
PDF & Excel (Site License)
USD 6696
PDF & Excel (Enterprise License)
USD 8035

Add to Cart

The global market for chronic kidney disease was valued at $52.9 billion in 2025 and is estimated to reach $82.6 billion by 2030, at a compound annual growth rate (CAGR) of 9.3% from 2025 through 2030.

The North American market for chronic kidney disease was valued at $24.6 billion in 2025 and is estimated to reach $37.5 billion by 2030, at a CAGR of 8.8% from 2025 through 2030.

The Asia-Pacific market for chronic kidney disease was valued at $9.1 billion in 2025 and is estimated to reach $15.4 billion by 2030, at a CAGR of 11.1% from 2025 through 2030.

Report Scope

The global market for chronic kidney disease is segmented by technology type, pharmaceutical drugs, and end users. From a technological perspective, the market is divided into diagnostic, therapeutic, and renal replacement solutions. Diagnostic technologies encompass biomarker-driven assays, imaging techniques, point-of-care testing, and genomic and proteomic screening, which facilitate early diagnosis and ongoing disease assessment. Therapeutic technologies encompass conventional drug treatments, innovative cell- and gene-based therapies, and advanced drug delivery systems, designed to slow disease progression and enhance patient outcomes. Renal replacement technologies, such as hemodialysis, peritoneal dialysis, and bioengineered artificial kidneys, are predominantly utilized in late-stage and end-stage CKD management.

In terms of pharmaceutical drugs, the market is segmented by CKD stage (Stage 1-5) and by medications used for dialysis and post-transplant care. This segmentation reflects the varying therapeutic requirements associated with disease severity and treatment settings. Based on end users, the market is classified into hospitals, clinics, and home-based or in-house dialysis settings. Hospitals and clinics account for the largest share due to comprehensive care capabilities, but the home care segment is experiencing rapid growth driven by increased patient preference, convenience, and advances in dialysis technologies. For market estimates, data has been provided for 2024 as the base year, 2025 as the estimated year, and with forecasts for 2026 through 2030.

Report Includes

  • 57 data tables and 43 additional tables
  • In-depth analysis of the global markets for chronic kidney diseases (CKD) and related technologies
  • Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
  • Estimates of the current market size and revenue forecasts, along with a corresponding market share analysis by product type, application, end-user and region
  • Facts and figures pertaining to the market dynamics, technological advances, regulations, prospects, reimbursement practices, and the impact of macroeconomic variables
  • Insights derived from Porter's Five Forces model, as well as global supply chain analyses
  • Information on current state of chronic kidney disease, with an emphasis on biomarkers, diagnostic methods and mobile apps that support effective disease state management
  • Key insight into research on CKD comorbidities such as diabetes and metabolic disease, as well as treatment methods and diagnostics
  • Review of key granted and published patents
  • Analysis of the industry structure, including companies' shares and global rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • Company profiles of major players within the industry, including Fresenius Medical Care AG, Baxter, B. Braun SE, NIPRO, and Medtronic
Product Code: HLC214B

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion

Chapter 2 Market Overview

  • Overview
  • Macroeconomic Factors Analysis
  • Growth in Healthcare Spending and Focus on Chronic Conditions
  • Aging Populations and Shifting Demographic Patterns
  • Economic Development, Urbanization, and Lifestyle-Related Health Risks
  • Investment in Healthcare Infrastructure and Broader Access to Care
  • Impact of U.S. Tariffs and Global Trade Dynamics
  • Porter's Five Forces Analysis
  • Potential for New Entrants to the Market
  • Bargaining Power of Suppliers
  • Bargaining Power of Buyers
  • Threat of Substitutes
  • Competition in the Industry

Chapter 3 Market Dynamics

  • Overview
  • Market Drivers
  • Growing Prevalence of Chronic Diseases Such as Diabetes and Hypertension Globally
  • Progression Rate from Early-Stage CKD to End-Stage Renal Disease (ESRD)
  • Increased Number of Dialysis Centers and Laboratories
  • Market Restraints
  • High Capital and High Cost of Treatment and Limited Reimbursement
  • Stringent Regulatory and Approval Requirements
  • Low Awareness and Late Diagnosis
  • Market Opportunities
  • Growing Investment in Regenerative Medicine and Biologic Therapies
  • Expanding Research and Development Efforts by Industry Leaders
  • Research and Development Initiatives from Key Companies

Chapter 4 Regulatory Landscape

  • Overview
  • Regulatory Scenario in the U.S.
  • Regulatory Scenario in Europe
  • Regulatory Scenario in Asia-Pacific
  • Japan
  • China
  • India
  • Regulatory Scenario in the Rest of the World

Chapter 5 Emerging Technologies and Patent Analysis

  • Overview
  • Emerging Trends/Technologies
  • Advanced Diagnostic Technologies
  • Novel Therapeutics and Biologics
  • Wearable and Implantable Renal Devices
  • Artificial Intelligence, Machine Learning, and Digital Health
  • Regenerative Medicine and Tissue Engineering
  • Patent Analysis

Chapter 6 Market Segmentation Analysis

  • Segmentation Breakdown
  • Market Breakdown by Technology
  • Takeaways
  • Diagnostic Technologies
  • Therapeutic Technologies
  • Renal Replacement Technologies
  • Market Breakdown by Pharmaceutical Drugs
  • Takeaways
  • Market Breakdown by End User
  • Takeaways
  • Geographic Breakdown
  • Market Breakdown by Region
  • Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America

Chapter 7 Competitive Intelligence

  • Competitive Analysis
  • Strategic Analysis
  • Investment Landscape

Chapter 8 Sustainability in the Chronic Kidney Disease Market: ESG Perspective

  • Overview
  • Sustainability Trends and Initiatives of AI in the Chronic Kidney Disease Industry
  • ESG Risk Ratings
  • Concluding Remarks from BCC Research

Chapter 9 Appendix

  • Research Methodology
  • Abbreviations
  • References
  • Company Profiles
  • ABBVIE INC.
  • AMGEN INC.
  • ASTELLAS PHARMA INC.
  • BAXTER
  • BAYER AG
  • B. BRAUN SE
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • FRESENIUS MEDICAL CARE AG
  • JOHNSON & JOHNSON
  • LILLY USA LLC
  • NOVARTIS AG
  • PFIZER INC.
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC INC.
  • TORAY INDUSTRIES INC.
  • Emerging Startups/Market Disruptors
Product Code: HLC214B

List of Tables

  • Summary Table : Global Market for Chronic Kidney Disease, by Region, Through 2030
  • Table 1 : U.S. Regulatory Pathways for Chronic Kidney Disease Market
  • Table 2 : European Regulatory Pathways for Chronic Kidney Disease Market
  • Table 3 : Global Regulatory Summary for Chronic Kidney Disease Market
  • Table 4 : Global Market for Chronic Kidney Diseases, by Technology, Through 2030
  • Table 5 : Global Market for Chronic Kidney Diseases, by Diagnostic Technology, Through 2030
  • Table 6 : Global Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
  • Table 7 : Global Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
  • Table 8 : Global Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
  • Table 9 : Global Market for Chronic Kidney Disease, by End User, Through 2030
  • Table 10 : Global Market for Chronic Kidney Disease, by Region, Through 2030
  • Table 11 : North American Market for Chronic Kidney Disease, by Technology, Through 2030
  • Table 12 : North American Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
  • Table 13 : North American Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
  • Table 14 : North American Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
  • Table 15 : North American Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
  • Table 16 : North American Market for Chronic Kidney Disease, by End User, Through 2030
  • Table 17 : North American Market for Chronic Kidney Disease, by Country, Through 2030
  • Table 18 : European Market for Chronic Kidney Disease, by Technology, Through 2030
  • Table 19 : European Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
  • Table 20 : European Market for Chronic Kidney Diseases, by Therapeutic Technology, Through 2030
  • Table 21 : European Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
  • Table 22 : European Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
  • Table 23 : European Market for Chronic Kidney Diseases, by End User, Through 2030
  • Table 24 : European Market for Chronic Kidney Disease, by Country, Through 2030
  • Table 25 : Asia-Pacific Market for Chronic Kidney Disease, by Technology, Through 2030
  • Table 26 : Asia-Pacific Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
  • Table 27 : Asia-Pacific Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
  • Table 28 : Asia-Pacific Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
  • Table 29 : Asia-Pacific Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
  • Table 30 : Asia-Pacific Market for Chronic Kidney Disease, by End User, Through 2030
  • Table 31 : Asia-Pacific Market for Chronic Kidney Disease, by Country, Through 2030
  • Table 32 : MEA Market for Chronic Kidney Disease, by Technology, Through 2030
  • Table 33 : MEA Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
  • Table 34 : MEA Market for Chronic Kidney Diseases, by Therapeutic Technology, Through 2030
  • Table 35 : MEA Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
  • Table 36 : MEA Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
  • Table 37 : MEA Market for Chronic Kidney Disease, by End User, Through 2030
  • Table 38 : MEA Market for Chronic Kidney Disease, by Country, Through 2030
  • Table 39 : South American Market for Chronic Kidney Disease, by Technology, Through 2030
  • Table 40 : South American Market for Chronic Kidney Disease, by Diagnostic Technology, Through 2030
  • Table 41 : South American Market for Chronic Kidney Disease, by Therapeutic Technology, Through 2030
  • Table 42 : South American Market for Chronic Kidney Disease, by Renal Replacement Technology, Through 2030
  • Table 43 : South American Market for Chronic Kidney Disease, by Pharmaceutical Drugs, Through 2030
  • Table 44 : South American Market for Chronic Kidney Disease, by End User, Through 2030
  • Table 45 : South American Market for Chronic Kidney Disease, by Country, Through 2030
  • Table 46 : Agreements, Collaborations, and Partnerships in the Chronic Kidney Diseases Market, 2023-2025
  • Table 47 : ESG Risk Rankings for Chronic Kidney Disease Market, 2025*
  • Table 48 : Abbreviations Used in this Report
  • Table 49 : AbbVie Inc.: Company Snapshot
  • Table 50 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
  • Table 51 : AbbVie Inc.: Product Portfolio
  • Table 52 : AbbVie Inc.: News/Key Developments, 2023-2025
  • Table 53 : Amgen Inc.: Company Snapshot
  • Table 54 : Amgen Inc.: Financial Performance, FY 2023 and 2024
  • Table 55 : Amgen Inc.: Product Portfolio
  • Table 56 : Amgen Inc.: News/Key Developments, 2023-2025
  • Table 57 : Astellas Pharma Inc.: Company Snapshot
  • Table 58 : Astellas Pharma Inc.: Financial Performance, FY 2023 and 2024
  • Table 59 : Astellas Pharma Inc.: Product Portfolio
  • Table 60 : Baxter: Company Snapshot
  • Table 61 : Baxter: Financial Performance, FY 2023 and 2024
  • Table 62 : Baxter: Product Portfolio
  • Table 63 : Baxter: News/Key Developments, 2024 and 2025
  • Table 64 : Bayer AG: Company Snapshot
  • Table 65 : Bayer AG: Financial Performance, FY 2023 and 2024
  • Table 66 : Bayer AG: Product Portfolio
  • Table 67 : B. Braun SE: Company Snapshot
  • Table 68 : B. Braun SE: Financial Performance, FY 2023 and 2024
  • Table 69 : B. Braun SE: Product Portfolio
  • Table 70 : Boehringer Ingelheim International GmbH: Company Snapshot
  • Table 71 : Boehringer Ingelheim International GmbH: Product Portfolio
  • Table 72 : Boehringer Ingelheim International GmbH: News/Key Developments, 2023-2024
  • Table 73 : Fresenius Medical Care AG: Company Snapshot
  • Table 74 : Fresenius Medical Care AG: Financial Performance, FY 2023 and 2024
  • Table 75 : Fresenius Medical Care AG: Product Portfolio
  • Table 76 : Fresenius Medical Care AG: News/Key Developments, 2024 and 2025
  • Table 77 : Johnson & Johnson: Company Snapshot
  • Table 78 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
  • Table 79 : Johnson & Johnson: Product Portfolio
  • Table 80 : Lilly USA LLC: Company Snapshot
  • Table 81 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
  • Table 82 : Lilly USA LLC: Product Portfolio
  • Table 83 : Novartis AG: Company Snapshot
  • Table 84 : Novartis AG: Financial Performance, FY 2023 and 2024
  • Table 85 : Novartis AG: Product Portfolio
  • Table 86 : Pfizer Inc.: Company Snapshot
  • Table 87 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
  • Table 88 : Pfizer Inc.: Product Portfolio
  • Table 89 : Pfizer Inc.: News/Key Developments, 2025
  • Table 90 : Siemens Healthineers AG: Company Snapshot
  • Table 91 : Siemens Healthineers AG: Financial Performance, FY 2024 and 2025
  • Table 92 : Siemens Healthineers AG: Product Portfolio
  • Table 93 : Thermo Fisher Scientific Inc.: Company Snapshot
  • Table 94 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
  • Table 95 : Thermo Fisher Scientific Inc.: Product Portfolio
  • Table 96 : Toray Industries Inc.: Company Snapshot
  • Table 97 : Toray Industries Inc.: Financial Performance, FY 2023 and 2024
  • Table 98 : Toray Industries Inc.: Product Portfolio
  • Table 99 : List of a Few Emerging Startups in the Global Chronic Kidney Disease Market

List of Figures

  • Summary Figure : Global Market Shares for Chronic Kidney Disease, by Region, 2024
  • Figure 1 : Porter's Five Forces Analysis: Chronic Kidney Disease Market
  • Figure 2 : Market Dynamics of Chronic Kidney Disease
  • Figure 3 : Patent Shares for Chronic Kidney Disease Market, by Jurisdiction, 2025
  • Figure 4 : Global Market Shares for Chronic Kidney Diseases, by Technology, 2024
  • Figure 5 : Global Market Shares for Chronic Kidney Diseases, by Diagnostic Technology, 2024
  • Figure 6 : Global Market Shares for Chronic Kidney Diseases, by Therapeutic Technology, 2024
  • Figure 7 : Global Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
  • Figure 8 : Global Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
  • Figure 9 : Global Market Shares for Chronic Kidney Disease, by End User, 2024
  • Figure 10 : Global Market Shares for Chronic Kidney Disease, by Region, 2024
  • Figure 11 : North American Market Shares for Chronic Kidney Disease, by Technology, 2024
  • Figure 12 : North American Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
  • Figure 13 : North American Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
  • Figure 14 : North American Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
  • Figure 15 : North American Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
  • Figure 16 : North American Market Shares for Chronic Kidney Disease, by End User, 2024
  • Figure 17 : North American Market Shares for Chronic Kidney Disease, by Country, 2024
  • Figure 18 : European Market Shares for Chronic Kidney Disease, by Technology, 2024
  • Figure 19 : European Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
  • Figure 20 : European Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
  • Figure 21 : European Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
  • Figure 22 : European Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
  • Figure 23 : European Market Shares for Chronic Kidney Disease, by End User, 2024
  • Figure 24 : European Market Shares for Chronic Kidney Disease, by Country, 2024
  • Figure 25 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Technology, 2024
  • Figure 26 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
  • Figure 27 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
  • Figure 28 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
  • Figure 29 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
  • Figure 30 : Asia-Pacific Market Shares for Chronic Kidney Disease, by End User, 2024
  • Figure 31 : Asia-Pacific Market Shares for Chronic Kidney Disease, by Country, 2024
  • Figure 32 : MEA Market Shares for Chronic Kidney Diseases, by Technology, 2024
  • Figure 33 : MEA Market Shares for Chronic Kidney Diseases, by Diagnostic Technology, 2024
  • Figure 34 : MEA Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
  • Figure 35 : MEA Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
  • Figure 36 : MEA Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
  • Figure 37 : MEA Market Shares for Chronic Kidney Disease, by End User, 2024
  • Figure 38 : MEA Market Shares for Chronic Kidney Disease, by Country, 2024
  • Figure 39 : South American Market Shares for Chronic Kidney Disease, by Technology, 2024
  • Figure 40 : South American Market Shares for Chronic Kidney Disease, by Diagnostic Technology, 2024
  • Figure 41 : South American Market Shares for Chronic Kidney Disease, by Therapeutic Technology, 2024
  • Figure 42 : South American Market Shares for Chronic Kidney Disease, by Renal Replacement Technology, 2024
  • Figure 43 : South American Market Shares for Chronic Kidney Disease, by Pharmaceutical Drugs, 2024
  • Figure 44 : South American Market Shares for Chronic Kidney Disease, by End User, 2024
  • Figure 45 : South American Market Shares for Chronic Kidney Disease, by Country, 2024
  • Figure 46 : Global Market Shares for Chronic Kidney Diseases, by Leading Companies, 2024
  • Figure 47 : AbbVie Inc: Revenue Share, by Country/Region, FY 2024
  • Figure 48 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 49 : Astellas Pharma Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 50 : Astellas Pharma Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 51 : BAXTER: Revenue Share, by Business Unit, FY 2024
  • Figure 52 : BAXTER: Revenue Share, by Country/Region, FY 2024
  • Figure 53 : Bayer AG: Revenue Share, by Business Unit, FY 2024
  • Figure 54 : Bayer AG: Revenue Share, by Country/Region, FY 2024
  • Figure 55 : B. Braun SE: Revenue Share, by Business Unit, FY 2024
  • Figure 56 : B. Braun SE: Revenue Share, by Country/Region, FY 2024
  • Figure 57 : Fresenius Medical Care AG: Revenue Share, by Business Unit, FY 2024
  • Figure 58 : Fresenius Medical Care AG: Revenue Share, by Country/Region, FY 2024
  • Figure 59 : Johnson & Johnson: Revenue Share, by Business Unit, FY 2024
  • Figure 60 : Johnson & Johnson: Revenue Share, by Country/Region, FY 2024
  • Figure 61 : Lilly USA LLC: Revenue Share, by Country/Region, FY 2024
  • Figure 62 : Novartis AG: Revenue Share, by Business Unit, FY 2024
  • Figure 63 : Novartis AG: Revenue Share, by Country/Region, FY 2024
  • Figure 64 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 65 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 66 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2025
  • Figure 67 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2025
  • Figure 68 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 69 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 70 : Toray Industries Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 71 : Toray Industries Inc.: Revenue Share, by Country/Region, FY 2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!